ClinicalTrials.gg
RecruitingNCT04347434CONTRAST-2Updated Nov 24, 2023

Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI

A Phase 4 interventional study of Atorvastatin 80mg in Myocardial Infarction, Acute, Myocardial Strain and Arterial Stiffness, sponsored by Penza State University. Recruiting at 1 site in Russian Federation. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Penza State University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing atorvastatin in Myocardial Infarction — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Myocardial Infarction.

Planned enrollment
3rd of 15
300 · median 120
Started
2020
the only one that year
Phase 4
9 of 15
1 open now
Registered
15th of 15
by date
Lead sponsor
2 of 15
Penza State University

Among the 15 studies testing atorvastatin in Myocardial Infarction, this one is the 3rd largest by planned enrollment, is the only one that started in 2020, is one of 9 in phase 4, and was the 15th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

1 of the 15 studies testing atorvastatin in Myocardial Infarction is open now, in 1 country.

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing atorvastatin in Myocardial Infarction, or all of them as a file.
02

Study summary

In a single-center, open-label, prospective, controlled, clinical study, it is planned to include 300 patients hospitalized in the cardiology department of SBHI Penza regional clinical hospital n.a. N.N. Burdenko. Recruitment of patients will be carried out at the Department of Therapy of the Medical Institute of the Penza State University. Patients meeting the inclusion criteria and not meeting the exclusion criteria will be included in the study.

Initially, lipid-lowering treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy.

If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.

Standard AMI treatment includes dual antiplatelet therapy, ACE inhibitors, beta-blockers (if indicated). Prescription of proton pump inhibitors and nitrates is possible (if indicated).

The total follow-up is 96 weeks. Prescreening - 600 people; screening and randomization - 300 people. Parameters of electrical myocardial heterogeneity, myocardial deformation characteristics, vascular rigidity, and quality of life will be assessed according to the study plan.

Read the detailed description

Methods

  1. Blood chemistry test. Total cholesterol, LDL, HDL, triglycerides, AST, ALT, CPK, glucose, CRP, creatinine, glycosylated hemoglobin
  2. 2D and 3D transthoracic echocardiography (Vivid GE 95 Healthcare (USA). 3D speckle echocardiography (3DSTE) for a detailed study of the phase-by-phase movement and spatial interaction of all muscle layers of the left ventricle in different phases of the cardiac cycle to obtain quantitative values of the deformation of the left ventricle individual segments in the longitudinal, circumferential and radial directions.

    The analysis of standard indicators of echocardiography: biplane ejection fraction according to the Simpson method, 3D ejection fraction, EDV (end-diastolic volume), ESV (end-systolic volume) and their indices. The left ventricular myocardial mass index (LVMI).

    Using a tissue doppler, the parameters characterizing the diastolic function are recorded: the LA volume, the early diastolic velocity of the mitral valve fibrous ring, the ratio of the early diastolic transmitral flow E to the average early diastolic speed of the fibrous ring e´, and the maximum tricuspid regurgitation rate.

    Myocardial strain is analyzed using specialized software - EchoPac Software Only (General Electric Co., 2018). For three-dimensional strain analysis, the left ventricle is automatically divided into 17 segments using standard segmentation schemes. The software allows obtaining strain values in the endocardial, middle and epicardial layers of the myocardium. Over a period of time, indicators for each segment are automatically calculated:

    longitudinal strain/strain rate (LS,%/LSR, cm / s-1), circumferential strain/strain rate (CS,%/CSR, cm / s-1), radial strain/strain rate(RS,%/RSR, cm / s-1), area strain), rotation, rotation along the axis of the left ventricle (Torsion).

  3. Long-term ECG monitoring over 3 leads with an assessment of the parameters of myocardial electrical instability A long-term ECG recording (120 hours) in patients with myocardial infarction will be performed using the Astrocard ECG system (CJSC Meditek, Russia) with 3-channel recorders. Long-term recordings will be analyzed separately for 3 time intervals: 24, 72 and 120 hours.

    Pauses of rhythm, rhythm disturbances - extrasystole, unstable tachycardia, AF paroxysm and atrial flutter, ventricular fibrillation, conduction disturbance will be recorded.

    Assessment of the ST segment dynamics will be carried out with detection of ischemia episodes, which will be detected when the ST segment is displaced ≥10 mV from the baseline 80 ms after the J point for at least 1 min - episodes of elevation and depression of the ST segment.

    According to the long-term ECG monitoring recordings, the following parameters will be analyzed (separately for 3 intervals - 24, 72 and 120 hours):

    circadian dynamics of heart rate; late ventricular potentials (LVP); variance and duration of the QT interval; heart rate variability (HRV); heart rate turbulence (TCP); chronotropic load (CL). Circadian dynamics of heart rate. The circadian dynamics of heart rate will be analyzed with an estimate of the minimum, average and maximum heart rate per day, during waking hours and night sleep. The circadian index (CI) will be defined as the ratio of the average heart rate in the daytime and the average heart rate in the night.

    LVP. The LVP will be evaluated in the standard averaging mode in the range of 40-100 Hz by the noise level not exceeding 0.9 μV. Records of the 24-h ECG in patients who have a decrease in intraventricular conduction, bundle branches blockade, will not be subjected to LVP analysis. An automatic analysis of late post-depolarization begins with a search for the QRS reference complex, which will be used later as a reference for averaging. Subsequently, the ECG signal will be processed programmatically by the time analysis method, at the end of which the following parameters will be evaluated: the width of the filtered QRS complex (QRSf), the duration of the low-amplitude potentials at the end of the QRS complex of the final part of the complex (HFLA), the rms value of the last 40 ms QRS (RMS ) Dispersion and QT interval duration. For a detailed study of the repolarization process in the analysis of records, close attention will be paid to the analysis of the duration, variability and variance of the QT interval.

    HRV. The following HRV time indicators will be considered:

    • Mean NN (ms) - average value of all RR-intervals;
    • SDNN (ms) - standard deviation of the average values of RR-intervals;
    • SDNNi (ms) - average value of standard deviations RR for 5-minute recording periods;
    • SDANN (ms) is the standard deviation of the mean values of the sinus intervals RR for 5 min;
    • rMSSD (ms) is the square root of the sum of the differences of subsequent RR intervals;
    • pNN50 (%) is the percentage of successive RR intervals differing by more than 50 ms;
    • HRVti - triangular index;
    • TINN is the index of triangular interpolation of the histogram of RR-intervals.

    HRV frequency parameters:

    • TotP (ms2) is the power of the total spectrum;
    • ULfP (ms2) - spectrum power in the ultralow frequency range;
    • VLfP (ms2) is the power of the spectrum within very low frequencies;
    • LfP (ms2) - low-frequency range of frequencies; HfP (ms2) - high-frequency component of HRV; L / H - an indicator of the balance of the vagosympathetic balance. Evaluation of the above HRV parameters will be carried out per day, night and day hours.

    TCP is characterized by two independent parameters - the beginning of turbulence (TO) and the slope of turbulence (TS).

    Heart CL is assessed by the level and duration of exceeding the actual (observed in the patient during monitoring) heart rate values of the threshold heart rate calculated individually according to the proposed formulas with differentiation for periods of wakefulness and night sleep:

    THR-W (bpm) = HRmax (bpm) × 0.45, where THR-W is the threshold value of the heart rate during wakeful hours in beats per minute, heart rate max is the age-appropriate value of the maximum possible heart rate in beats per minute, 0.45 is the coefficient of the threshold level of heart rate; THR-S (bpm) = THR-W (bpm): 1.24, where THR-S (bpm) is the threshold value of the heart rate during the night's sleep.

  4. Ultrasound of the common carotid arteries with RF high frequency signal technology The study of local vascular stiffness by high-frequency RF signal technology using ultrasound of the common carotid arteries (CCA) will be carried out in B mode using MyLab 90 (Esaote, Italy).

    The RF signal technology includes two programs: RF-QIMT and RF-QAS. The following CCA indicators are analyzed: IMT - intima-media thickness, loc Psys - local systolic pressure in the carotid artery, loc Pdia - local diastolic pressure, P (T1) - pressure at the local point, stiffness indices β and α, DC is the coefficient of lateral distensibility, CC - coefficient of lateral compliance, Aix is the augmentation index, AP is the amplification pressure, PWV is the local pulse wave velocity in the carotid artery.

  5. Ultrasound of the brachiocephalic and femoral arteries The brachiocephalic and femoral arteries will be scanned using a Vivid GE 95 ultrasound scanner (Healthcare, USA) using a linear sensor in B-mode, spectral Doppler imaging and color Doppler imaging.

    Quantitative analysis of atherosclerotic plaque includes determining the extent and degree of narrowing of the lumen of the vessel (percentage of stenosis) by the cross-sectional area (Sa) of the vessel:

    Sa = (A1 - A2) × 100% / A1, where A1 is the true cross-sectional area of the vessel, A2 is the passable cross-sectional area of the vessel.

  6. Applanation tonometry. SphygmoCor apparatus (AtCor Medical, Australia) uses pulsed wave to calculate the characteristics of central pressure in aorta.

    The applanation tonometry technique includes two programs: PWA and PWV. The first allows to record central aortic pressure indicators: systolic aortic pressure - SBPao, diastolic - DBPao, pulse - PPao, mean hemodynamic - MBPao based on registration of the radial artery PWV. Using the PWV program, sequential recording of PWV from the common carotid and femoral arteries simultaneously with the ECG channel analyzes the PWV in the aorta (cfPWV).

  7. Volume sphygmography. The measurements will be carried out with the VS-1000 device (Fukuda Denshi, Japan) while simultaneously recording plethysmograms on four limbs (using cuffs), ECG, phonocardiogram, and PWV on the carotid and femoral arteries.

    PWV is evaluated in different parts of the circulatory system (i.e., aorta (PWV), predominantly elastic arteries (R/L-PWV) and predominantly muscular arteries (B-PWV)).

    Cardio-Ankle Vascular Index (CAVI) is determined - an indicator that reflects the true stiffness of the vascular wall. CAVI is calculated by registering PWV at two points and measuring SBP and DBP. Additionally augmentation index and biological age will be calculated automatically.

  8. Flow-mediated dilation. Endothelial function is evaluated by ultrasonic determination of flow-mediated dilation (FMD) during the postocclusive reactive hyperemia test using the method described by D. Celenmajer et. al.
  9. Six-minute walk (6MW) test. The patient should not take cardiological drugs and should not smoke within at least 2 hours before the test. Before the 6MW test, the patient should have a 10-minute quiet rest in a sitting position. During this rest period, the following text should be read to the patient: "You will have to walk for 6 minutes, without using continuous running or alternate running and walking, with the aim to cover a maximum distance. You will walk back and forth along the corridor. You can slow down the pace, stop and have a rest in case of dyspnea or weakness. You can lean against the wall during rest. Then, you will have to resume the walk. Remember that your aim is to cover maximum distance in 6 minutes." At the 6-minute time point, the patient should be asked to stop and stand still until the covered distance has been measured.
  10. Computer Pulse Oximetry. During the 6-minute walk test, computer pulse oximetry is planned on a PulseOx 7500 instrument (SPO medical, Israel) to study saturation dynamics in comparison groups.
  11. Treatment compliance will be evaluated by standard methods (counting the remaining tablets). Morisky-Green Questionnaire
  12. Quality of Life Assessment. The following questionnaires are planned to be completed: Seattle Angina Questionnaire (SAQ), Minnesota Questionnaire, Clinical Assessment Scale for CHF (MQCAS) (modified by Mareev VY, 2000), analog-visual scale.
  13. Assessment of physical activity. It is planned to fill out a questionnaire for assessing the level of physical activity and a short international questionnaire for determining the physical activity of the International Questionnaire On Physical Activity - IPAQ
  14. Assessment of Anxiety Depression. An analysis of anxiety and depressive disorders in patients using the hospital scale of anxiety and depression (HADS) is planned
03

Conditions studied

  • Myocardial Infarction, Acute
  • Myocardial Strain
  • Arterial Stiffness
  • Quality of Life

Keywords

  • STEMI
  • NSTEMI
  • myocardial strain,
  • arterial stiffness,
  • lipid-lowering therapy,
  • electrical myocardial heterogeneity
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form 2 Primary STEMI or NSTEMI confirmed by , troponin I and CPK-MB levels, coronary angiography.
  1. Presence of an infarct-related artery according to coronary angiography.

Exclusion criteria

Exclusion Criteria:

  1. Presence of hemodynamically relevant stenosis exceeding 30% in several coronary arteries confirmed by CAG;
  2. Recurrent or repeated myocardial infarction.
  3. Exogenous hypertriglyceridemia (type 1 hyperchilomicronemia).
  4. The development of acute heart failure III-IV prior to randomization
  5. Individual intolerance to statins, ezetimibe.
  6. Congenital and acquired heart diseases.
  7. Severe concomitant diseases in the stage of decompensation.
  8. Non-sinus rhythm, established artificial pacemaker.
  9. Sinoatrial and atrioventricular blockade of 2-3 degrees.
  10. QRS complex exceeding 100 ms.
  11. The presence of severe LV hypertrophy according to echocardiography.
  12. Uncontrolled hypertension with SBP> 180 mm Hg and DBP> 110 mmHg
  13. Diabetes mellitus (DM) type 1 and 2.
  14. Current existence of severe anemia ( \< 100 g/L)
  15. Chronic kidney disease ( less than 30 ml / min / 1.73 m2 according to the ).
  16. Non-corrected thyroid dysfunction with hyper / hypothyroidism.
  17. (BMI) ≥35 kg / m2.
  18. Pregnancy, lactation.
  19. Alcohol abuse, drug addiction.
  20. Other serious concomitant diseases that exclude the possibility of study participation.
  21. Participation in other clinical trials within the last two months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Atorvastatin 80 mg

    Treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy. If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.

    Drug: Atorvastatin 80mg

  • Active comparator
    Atorvastatin-Ezetimibe

    In the absence of reaching the target level of LDL-C of ≤1.4 mmol / L and a decrease in the indicator by ≥50% after 5-6 weeks from the onset of AMI, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.

    Drug: Atorvastatin 80mg

Interventions

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy

    Also known as: Ezetimibe

06

What researchers measure

Primary outcomes

  1. Ventricular arrhythmias

    Statistically significant differences in the frequency of ventricular arrhythmias as compared to controls

    Time frame: up to 48 months

  2. Systolic function

    Statistically significant differences in systolic function of the left ventricle according to transthoracic echocardiography as compared to controls;

    Time frame: up to 48 months

  3. Myocardial deformation of the LA and LV

    Statistically significant differences in the myocardial deformation of the LA and LV as compared to controls

    Time frame: up to 48 months

  4. PCI / CABG for a new case of coronary atherosclerosis, hospitalization for unstable angina

    Statistically significant differences for major coronary events - PCI / CABG for a new case of coronary atherosclerosis, hospitalization for unstable angina as compared to controls

    Time frame: up to 48 months

  5. Myocardial electrical instability

    Statistically significant differences in the late ventricular potentials, heart rate variability, QT interval dispersion (ms) as compared to controls

    Time frame: up to 120 hours for 2 years period

  6. Heart rate turbulence

    Statistically significant differences in the parameters of heart rate turbulence (%) as compared to controls

    Time frame: up to 120 hours for 2 years period

Secondary outcomes

  1. Cardiovascular mortality

    Statistically significant differences for incidence of CV events as compared to controls

    Time frame: up to 48 months

  2. Frequency of repeated fatal / non-fatal MI

    Statistically significant differences in the frequency of repeated fatal / non-fatal MI as compared to controls

    Time frame: up to 48 months

  3. Hospitalization due to acute decompensation of heart failure

    Statistically significant differences according to the frequency of hospitalization due to acute decompensation of heart failure as compared to controls

    Time frame: up to 48 months

  4. Structural state of arteries different types

    Statistically significant differences in pulse wave velocities in arteries of various calibers, as compared to controls

    Time frame: up to 48 months

  5. Structural state of carotid artery

    Statistically significant differences in intima-media thickness of carotid artery according ultrasound, as compared to controls

    Time frame: up to 48 months

  6. Functional state of arteries

    Statistically significant differences in flow-mediated dilation parameters (diameter of brachial artery, mm) assessed by ultrasound, as compared to controls

    Time frame: up to 48 months

  7. Progression of CHF, exercise tolerance

    Statistically significant differences in 6-minute walk test (distance covered, m), as compared to controls

    Time frame: up to 48 months

  8. Progression of CHF, laboratory data

    Statistically significant differences in BNP level (pg/ml), as compared to controls

    Time frame: up to 48 months

  9. Left ventricular remodeling

    Statistically significant differences echocardiographic parameters of left ventricle pathological remodeling (ejection fraction, %, EDVi, ESVi) as compared to controls

    Time frame: up to 48 months

  10. Lipid profile

    Statistically significant differences of lipid profile (mmol/l) as compared to controls

    Time frame: up to 48 months

  11. Laboratory parameters

    Statistically significant differences of CRP (mg/l) as compared to controls

    Time frame: up to 48 months

  12. Angina episodes

    Statistically significant differences on angina episodes assessed by Seattle Angina Questionnaire (min - 19, max - 108 better outcome), as compared to controls

    Time frame: up to 48 months

  13. Quality of life questionnaire

    Statistically significant differences according to the quality of life of patients assessed by Minnesota Questionnaire (min -0, max-105, worse outcome), as compared to controls

    Time frame: up to 48 months

  14. Quality of life questionnaire in СHF

    Statistically significant differences according to the quality of life of patients assessed by Clinical Assessment Scale for CHF(min -0, max-20, worse outcome), as compared to controls

    Time frame: up to 48 months

  15. Patients wellbeing

    Statistically significant differences of patients wellbeing according to the analog-visual scale , as compared to controls

    Time frame: up to 48 months

07

Study locations

1 of 1 sites recruiting
  • Valentin Oleynikov
    Penza, 440026, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Nov 2027, 93 months after the start.

Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 93 months is above that.

Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2020
First posted
Apr 15, 2020
StartActual
Feb 12, 2020
Primary completionEst.
Nov 12, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04347434
Lead sponsor
Penza State University
Responsible party
Valentin Oleynikov (DM, Penza State University) — Principal investigator
First posted
Apr 15, 2020
Start date
Feb 12, 2020
Primary completion
Nov 12, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 24, 2023

Study contacts

Nadezhda V Burko, PhD
Contact
hopeful.n@mail.ru
+78412548229
Valentin E Oleynikov, DM
principal investigator · Penza State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion